Massive Genomic Study Identifies FNIP1 'Skinny Gene' Mutation That Mimics GLP-1 Drug Effects
Key Insights
Scientists sequenced over one million genomes across three continents and identified rare FNIP1 (search) loss-of-function variants linked to a 60% lower risk of cardiometabolic diseases.
Carriers of the mutation—roughly one in 7,000 people—show lower blood lipids, less liver fat, lower blood sugar, and proportionally more muscle.
The FNIP1 (search) gene normally slows cellular calorie-burning machinery; disabling it causes the body to burn energy faster and use fat instead of storing it.
A sweeping genomic analysis encompassing more than one million individuals across three continents has pinpointed rare mutations in the FNIP1 (search) gene that confer striking protection against obesity (search), type 2 diabetes (search), heart disease, and other cardiometabolic conditions. The findings, published in Nature, reveal that roughly one in every 7,000 people carries a broken copy of FNIP1—and those who do exhibit metabolic profiles that researchers liken to the effects of GLP-1 receptor agonist drugs.
"These individuals consume, store and utilize energy more than individuals without those mutations, and that's the protective factor," said Luca Lotta, a geneticist at Regeneron Pharmaceuticals and the study's co-senior author.
The study, led by the Regeneron Genetics Center in Tarrytown, New York, deployed advanced DNA sequencing to scour the coding regions of genomes from diverse populations. The team searched for genetic variants associated with changes in the TG:HDL ratio—the ratio of triglycerides to high-density lipoprotein cholesterol—a blood biomarker tightly linked to metabolic disease risk. "The higher this ratio is, the higher the risk of metabolic disease," Lotta explained.
FNIP1 (search) emerged as the standout gene. The protein it encodes partners with another protein called folliculin to put the brakes on cells' calorie-burning machinery, a mechanism that historically helped humans conserve energy during periods of food scarcity. But when one copy of the gene is disabled, the opposite occurs: the body burns through energy faster and preferentially uses fat rather than storing it, according to Viktoria Gusarova, a Regeneron researcher and study co-author.
Clinical Profile of Mutation Carriers
Among the approximately 150 individuals in the study who inherited a loss-of-function FNIP1 (search) variant, researchers documented a constellation of metabolic advantages. These carriers had lower blood lipids, reduced liver fat, lower blood sugar levels, and proportionally more muscle mass. Most notably, they demonstrated roughly 60 percent lower odds of developing cardiometabolic diseases, including obesity (search) and diabetes.
The rarity of these protective mutations reflects an evolutionary mismatch, Lotta noted. "Nowadays, we are living in a very calorie-rich environment, and historically there's no precedent for this. These incredibly rare mutations, which might have been unfavorable for many millennia, are now favorable to the body."
Preclinical Validation in Mouse Models
To validate the gene's therapeutic potential, the research team conducted laboratory experiments silencing FNIP1 (search) in liver cells, confirming that doing so activates fat-burning genes. In mice fed a high-fat, high-sugar diet, shutting down the FNIP1 pathway in the liver curbed weight gain, cleared fat deposits, and improved insulin sensitivity. Over a 30-week period, the intervention also prevented the fibrosis and liver damage that the obesogenic diet would otherwise induce.
Therapeutic Implications
The findings position FNIP1 (search) as a compelling drug target for cardiometabolic diseases, which Lotta described as "the number one cause of death in the world." The study exemplifies how naturally occurring loss-of-function variants can illuminate therapeutic pathways.
"Individuals with loss-of-function genetic variants can naturally mimic effects of pharmacologic inhibitors, and such studies have led to important therapeutic advances in other diseases," said Svati Shah, director of the Center for Precision Health at Duke University, who was not involved in the research.
Whether deliberately switching off FNIP1 (search) in humans will prove safe remains an open question. The study authors and external experts alike caution that further investigation is needed to assess the long-term consequences of pharmacologically targeting this pathway before any drug development can advance to clinical testing.